These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 15095224)

  • 1. Increase in sexual risk behavior associated with immunologic response to highly active antiretroviral therapy among HIV-infected injection drug users.
    Tun W; Gange SJ; Vlahov D; Strathdee SA; Celentano DD
    Clin Infect Dis; 2004 Apr; 38(8):1167-74. PubMed ID: 15095224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sexual risk behavior in HIV-infected injection drug users.
    Battegay M; Bucher HC; Vernazza P
    Clin Infect Dis; 2004 Apr; 38(8):1175-7. PubMed ID: 15095225
    [No Abstract]   [Full Text] [Related]  

  • 3. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study.
    Dragsted UB; Mocroft A; Vella S; Viard JP; Hansen AB; Panos G; Mercey D; Machala L; Horban A; Lundgren JD;
    J Infect Dis; 2004 Jul; 190(1):148-55. PubMed ID: 15195254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes among antiretroviral-naive human immunodeficiency virus-infected patients with small increases in CD4+ cell counts after successful virologic suppression.
    Dronda F; Moreno S; Moreno A; Casado JL; Pérez-Elías MJ; Antela A
    Clin Infect Dis; 2002 Oct; 35(8):1005-9. PubMed ID: 12355389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.
    Wood E; Montaner JS; Yip B; Tyndall MW; Schechter MT; O'Shaughnessy MV; Hogg RS
    Antivir Ther; 2004 Apr; 9(2):229-35. PubMed ID: 15134185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease.
    Hoffmann C; Chow KU; Wolf E; Faetkenheuer G; Stellbrink HJ; van Lunzen J; Jaeger H; Stoehr A; Plettenberg A; Wasmuth JC; Rockstroh J; Mosthaf F; Horst HA; Brodt HR
    Br J Haematol; 2004 May; 125(4):455-62. PubMed ID: 15142115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of race/ethnicity on the outcome of highly active antiretroviral therapy for human immunodeficiency virus type 1-infected patients.
    Jensen-Fangel S; Pedersen L; Pedersen C; Larsen CS; Tauris P; Møller A; Sørensen HT; Obel N
    Clin Infect Dis; 2002 Dec; 35(12):1541-8. PubMed ID: 12471575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy.
    Tarwater PM; Parish M; Gallant JE
    Clin Infect Dis; 2003 Dec; 37(11):1541-8. PubMed ID: 14614678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus.
    del Giudice P; Mary-Krause M; Pradier C; Grabar S; Dellamonica P; Marty P; Gastaut JA; Costagliola D; Rosenthal E;
    J Infect Dis; 2002 Nov; 186(9):1366-70. PubMed ID: 12402211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Directly observed antiretroviral therapy for injection drug users with HIV infection.
    Clarke S; Keenan E; Ryan M; Barry M; Mulcahy F
    AIDS Read; 2002 Jul; 12(7):305-7, 312-6. PubMed ID: 12161852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of total lymphocyte count for monitoring response to antiretroviral therapy.
    Schreibman T; Friedland G
    Clin Infect Dis; 2004 Jan; 38(2):257-62. PubMed ID: 14699459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between the rate of CD4+ T cell decrease and the year of human immunodeficiency virus (HIV) type 1 seroconversion among persons enrolled in the Swiss HIV cohort study.
    Vanhems P; Lambert J; Guerra M; Hirschel B; Allard R
    J Infect Dis; 1999 Dec; 180(6):1803-8. PubMed ID: 10558934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of preventive interventions by persons infected with type-1 human immunodeficiency virus (HIV-1). The Pulmonary Complications of HIV Study Group.
    Glassroth J; Jordan M; Wallace JM; Kvale PA; Follmann DA; Rosen MJ; Reichman LB; Mossar M; Hopewell PC
    Am J Prev Med; 1994; 10(5):259-66. PubMed ID: 7848668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
    Kahn JO; Martin JN; Roland ME; Bamberger JD; Chesney M; Chambers D; Franses K; Coates TJ; Katz MH
    J Infect Dis; 2001 Mar; 183(5):707-14. PubMed ID: 11181146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparations for AIDS vaccine trials. Incident human immunodeficiency virus (HIV) infections in a cohort of injection drug users in Baltimore, Maryland.
    Nelson KE; Vlahov D; Galai N; Astemborski J; Solomon L
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S201-5. PubMed ID: 7865301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of isoniazid treatment for latent tuberculosis infection among human immunodeficiency virus (HIV)-infected and HIV-uninfected injection drug users in methadone programs.
    Scholten JN; Driver CR; Munsiff SS; Kaye K; Rubino MA; Gourevitch MN; Trim C; Amofa J; Seewald R; Highley E; Fujiwara PI
    Clin Infect Dis; 2003 Dec; 37(12):1686-92. PubMed ID: 14689352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to antiretroviral therapy and its association with sexual behavior in a national sample of women with human immunodeficiency virus.
    Wilson TE; Barrón Y; Cohen M; Richardson J; Greenblatt R; Sacks HS; Young M;
    Clin Infect Dis; 2002 Feb; 34(4):529-34. PubMed ID: 11797182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease.
    Erbelding EJ; Chaisson RE; Gallant JE; Moore RD
    Antivir Ther; 1997 Apr; 2(2):71-7. PubMed ID: 11322278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continued high risk behaviors in HIV infected drug abusers.
    Miguez-Burbano MJ; Pineda-Medina L; Lecusay R; Page JB; Castillo G; Burbano X; Rodriguez A; Rodriguez N; Shor-Posner G
    J Addict Dis; 2002; 21(4):67-80. PubMed ID: 12296503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA.
    Murphy DA; Wilson CM; Durako SJ; Muenz LR; Belzer M;
    AIDS Care; 2001 Feb; 13(1):27-40. PubMed ID: 11177463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.